mRNA-1283 Next-Gen COVID-19 Vaccine
COVID-19 Prevention (Omicron-specific)
Sponsor Moderna
25,000 Enrollment Target
180 Trial Sites
5 Countries
September 2026 Est. Completion
About This Trial
Next-generation mRNA vaccine targeting multiple Omicron subvariants with improved durability and broader protection.
Primary Endpoints
- Neutralizing antibody response
- Vaccine efficacy against symptomatic infection
Latest Update
February 2026
Interim analysis shows 78% efficacy against symptomatic infection. Strong T-cell responses observed across age groups.
Lead Investigators
DJ
Dr. Jacqueline Miller Senior VP, Infectious Disease Development